中国医药行业面临资金和资产价值实现挑战，同时迎来新机遇近年来，中国医药行业在政策、市场和资本的多重影响下，经历了快速发展和深刻变革。然而，随着行业竞争的加剧和宏观经济环境的变化，医药企业正面临资金压力

Patient-centered drug development concept is deeply rooted in people's heartsIn recent years, with the advancement of medical technology and the increase in society's demand for health,Patient-Centric Drug Development (PCDD)The concept has gradually become the core trend of the global pharmaceutical

Promote the development of traditional Chinese medicine service trade and support the construction of national traditional Chinese medicine service export basesIn recent years, the influence of traditional Chinese medicine on a global scale has been continuously increasing, becoming an important gro

Rongchang BioTatisip's first biopharmaceutical for Sjogren's syndrome market application was accepted by CDERecently, Rongchang Biopharma (Yantai) Co., Ltd. (hereinafter referred to as "Rongchang Biopharma") announced that its independently developed innovative biopharmaceutical Tatecip (RC18) for t

Green manufacturing and sustainable development concepts are gradually integrated into the pharmaceutical industryIn recent years, with the global emphasis on environmental protection and sustainable development, the pharmaceutical industry has also been actively exploring green manufacturing and su

Clinical trial of gene therapy CAP-002 suspends due to first patient deathRecently, a shocking news has been received in the field of gene therapy: the highly-watched CAP-002 clinical trial was forced to be suspended due to the first patient's death. This incident quickly became the focus of hot dis

International cooperation and opening up are still important driving forces for pharmaceutical innovationIn the context of globalization, innovation and development in the pharmaceutical field are increasingly dependent on international cooperation and opening up. Hot topics in the past 10 days show

Many Grade A hospitals have been punished for medical insurance violations: Industry reflections on stricter supervisionRecently, the National Health Insurance Administration has released a number of penalties for medical insurance violations in medical institutions, involving many Grade A hospitals

Bailitianheng iza-bren (EGFR×HER3 dual anti-ADC) was recognized as the 6th breakthrough treatment for CDE, and is used for platinum-resistant recurrent ovarian cancer, etc.Recently, Baili Tianheng's innovative drug iza-bren (EGFR×HER3 dual anti-ADC) was awarded the 6th breakthrough treatment certi

CDE solicits opinions on the "Detailed Rules for Application and Management of Class I Conferences in Advanced Therapeutic Drug Communication", aiming to accelerate the review of cell and gene therapy drugsRecently, the Drug Review Center (CDE) of the State Drug Administration issued the "Detailed R